|
BioTech |
EiG serves emerging biotech and pharma companies experiencing
change. Our team provides human capital expertise in successfully navigating a pathway
that increases value. We are experts in working with senior management as well as
working with scientists on developing better leadership and management skills. Some
recent examples of our clients are as follows:
www.phenomix.com |
Phenomix is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. They designed their product candidates to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Their lead product candidate, PHX1149, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that they are developing as an oral, once-daily treatment for Type 2 diabetes. Their second product candidate, PHX1766, is a protease inhibitor currently in preclinical development for the treatment of hepatitis C virus, or HCV, infection.
|
www.proteolix.com
South San Francisco,
California USA |
Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing
and marketing pharmaceutical products that target certain cancers by inhibiting
the proteasome and thereby disrupting protein turnover in cells, particularly cancer
cells, which leads to cell death. Proteolix is developing next generation proteasome
inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome
inhibitor, to expand the therapeutic potential of this new target class. |
www.avigen.com
|
Avigen is a biopharmaceutical company focused on unique small molecule therapeutics
and biologics to treat serious neurological disorders, including neuropathic pain
and neuromuscular spasm and spasticity. Avigen's strategy is to complete the requirements
of clinical development for each of the candidates in its product pipeline, and
continue to look for opportunities to expand its pipeline through a combination
of internal research, acquisitions, and in-licensing, with the goal of becoming
a fully integrated commercial biopharmaceutical company committed to its small molecule
and biologics neurology products. |
www.proacta.com
San Diego, California USA
|
Proacta is focused on the treatment of tumors by exploiting their abnormally low
concentrations of oxygen (hypoxia). Hypoxia is present in the majority of solid
tumors and makes treatment with conventional chemotherapy and radiation less likely
to succeed.
Proacta's drugs are delivered as innocuous compounds that are selectively activated
in hypoxic regions of tumors. This can result in killing not only the hypoxic cells
but also the surrounding tumor cells which have more normal levels of oxygen.
|
www.prosetta.com
San Francisco, California USA
|
The mission of Prosetta Corporation is to bring to practical application a number
of basic discoveries in cell biology that have been made in the academic laboratories
of its founders. These discoveries, which fall into two broad categories, have enormous
potential for drug development and the individualization of medical therapeutics. |
A sampling of some of the investors and venture capital firms investing in our clients:
|
|
|
|
